Checkpoint Therapeutics (NASDAQ:CKPT) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a report issued on Wednesday,Benzinga reports. They currently have a $20.00 price target on the stock.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ CKPT opened at $4.08 on Wednesday. Checkpoint Therapeutics has a 1 year low of $1.36 and a 1 year high of $4.50. The company’s 50-day moving average is $3.23 and its 200 day moving average is $2.56. The stock has a market capitalization of $199.24 million, a P/E ratio of -2.22 and a beta of 1.34.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). Research analysts anticipate that Checkpoint Therapeutics will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CKPT. Vanguard Group Inc. grew its holdings in Checkpoint Therapeutics by 67.4% in the first quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock worth $1,882,000 after purchasing an additional 369,586 shares during the period. B. Riley Wealth Advisors Inc. grew its holdings in Checkpoint Therapeutics by 366.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock worth $493,000 after purchasing an additional 180,050 shares during the period. PVG Asset Management Corp purchased a new stake in shares of Checkpoint Therapeutics during the second quarter valued at approximately $295,000. Geode Capital Management LLC grew its holdings in shares of Checkpoint Therapeutics by 41.2% during the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after buying an additional 124,787 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after buying an additional 80,000 shares during the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.